Meldonium decreases the diet-increased plasma levels of trimethylamine n-oxide, a metabolite associated with atherosclerosis

Journal of Clinical Pharmacology

Volumn 53, Issue 10, 2013, Pages 1095-1098

  Dambrova, Maija ^a,b   Skapare makarova, Elina ^a   Konrade, Ilze ^b   Pugovics, Osvalds ^a   Grinberga, Solveiga ^a   Tirzite, Dace ^a   Petrovska, Ramona ^c   Kalvins, Ivars ^a   Liepins, Edgars ^a  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

^c Biomedical Research Study Centre   (Latvia)

Author keywords

Meldonium; Trimethylamine; Trimethylamine n oxide; Uplc ms ms; Urinary excretion

Indexed keywords

CARNITINE; MELDONIUM; ORGANIC CATION TRANSPORTER 2; TRIMETHYLAMINE OXIDE;

ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; DIET; FEMALE; HEART PROTECTION; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; URINALYSIS;

MELDONIUM; TRIMETHYLAMINE; TRIMETHYLAMINE N-OXIDE; UPLC/MS/MS; URINARY EXCRETION;

ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CARNITINE; DIET; FEMALE; HEK293 CELLS; HUMANS; MALE; METHYLAMINES; METHYLHYDRAZINES; ORGANIC CATION TRANSPORT PROTEINS; SEAFOOD;

EID: 84885164095     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.135     Document Type: Article

References (19)

1. Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med. 2002;12:275-279. (Pubitemid 35286766)
2. Kuka J, Vilskersts R, Cirule H, et al. The cardioprotective effect of mildronate is diminished after co-treatment with L-carnitine. J Cardiovasc Pharmacol Ther. 2012;17:215-222.
3. Liepinsh E, Konrade I, Skapare E, et al. Mildronate treatment alters gamma-butyrobetaine and L-carnitine concentrations in healthy volunteers. J Pharm Pharmacol. 2011;63:1195-1201.
4. Simkhovich BZ, Shutenko ZV, Meirena DV, et al. 3-(2, 2, 2- Trimethylhydrazinium)propionate (THP)-a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol. 1988;37:195-202.
5. Kuwajima M, Harashima H, Hayashi M, et al. Pharmacokinetic analysis of the cardioprotective effect of 3-(2, 2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. J Pharmacol Exp Ther. 1999;289:93-102. (Pubitemid 29156017)
6. Liepinsh E, Vilskersts R, Loca D, et al. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J Cardiovasc Pharmacol. 2006;48:314-319. (Pubitemid 46066837)
7. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of Lcarnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004;1033:30-41. (Pubitemid 39656736)
8. Bain MA, Milne RW, Evans AM. Disposition and metabolite kinetics of oral L-carnitine in humans. J Clin Pharmacol. 2006;46:1163-1170. (Pubitemid 44387416)
9. Rebouche CJ, Seim H. Carnitine metabolism and its regulation in microorganisms and mammals. Annu Rev Nutr. 1998;18: 39-61. (Pubitemid 28366860)
10. al-Waiz M, Mikov M, Mitchell SC, Smith RL. The exogenous origin of trimethylamine in the mouse. Metabolism. 1992;41:135- 136.
11. Kawai T. Fish flavor. Crit Rev Food Sci Nutr. 1996;36:257-298. (Pubitemid 126444288)
12. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57-63.
13. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576-585.
14. Lloyd AJ, Fave G, Beckmann M, et al. Use of mass spectrometry fingerprinting to identify urinary metabolites after consumption of specific foods. Am J Clin Nutr. 2011;94:981-991.
15. Zhang AQ, Mitchell SC, Smith RL. Dietary precursors of trimethylamine in man: a pilot study. Food Chem Toxicol. 1999;37:515-520. (Pubitemid 29306917)
16. al-Waiz M, Mitchell SC, Idle JR, Smith RL. The metabolism of 14Clabelled trimethylamine and its N-oxide in man. Xenobiotica. 1987;17:551-558. (Pubitemid 17091471)
17. Bain MA, Faull R, Fornasini G, Milne RW, Evans AM. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant. 2006;21:1300-1304.
18. Karpov RS, Dudko VA, Shipulin VM, et al. The clinical instrumental evaluation of treatment efficacy in patients with concomitant atherosclerosis of the coronary, cerebral and peripheral arteries. Ter Arkh. 1991;63:90-93.
19. Vilskersts R, Liepinsh E, Mateuszuk L, et al. Mildronate, a regulator of energy metabolism, reduces atherosclerosis in apoE/LDLR-/- mice. Pharmacology. 2009;83:287-293.